Clinical Trial Detail

NCT ID NCT02953561
Title Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Avelumab + Azacitidine

Age Groups: adult senior

No variant requirements are available.